Evaluation of spironolactone nanoparticles coated with chitosan topical preparation effect on acne
Phase 2
Completed
- Conditions
- Acne vulgarisL70.0acne vulgaris.
- Registration Number
- IRCT20120707010203N11
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients with mild to moderate acne, defined as a score of 1 to 30 on the global acne grading system (GAGS) scale.
Patients which received no previous acne therapies participated in the study, or have not received any treatment before this study
Exclusion Criteria
Patients which received topical anti-acne therapy two months before or during the study or any systemic therapy with antibiotics, OCP, retinoid, and spironolactone before or during the study
Patients were excluded if they had other disease;
Pregnant, or planning to become pregnant women
Lactating
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method o. of lesions. Timepoint: At the beginning of study (time zero) and 2, 4 and 8 weeks after treatment. Method of measurement: clinical evaluation.
- Secondary Outcome Measures
Name Time Method esion kind (inflammatory or non-inflammatory). Timepoint: At the beginning of study (time zero) and 2, 4 and 8 weeks after treatment. Method of measurement: Clinical evaluation.